Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression

被引:4
|
作者
Wu, Tianying [1 ,2 ]
Kasper, Susan [3 ]
Wong, Ronnie Meiyi [1 ]
Bracken, Bruce [4 ]
机构
[1] San Diego State Univ, Div Epidemiol & Biostat, Sch Publ Hlth, Hardy Tower,Rm 172,5500 Campanile Dr, San Diego, CA 92182 USA
[2] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA
[3] Univ Cincinnati, Dept Environm Hlth, Med Sch, Cincinnati, OH USA
[4] Univ Cincinnati, Dept Surg, Med Sch, 231 Bethesda Ave, Cincinnati, OH 45267 USA
关键词
Glycation; Lipid oxidation; Metal oxidation; Oxidative stress; PSA; GLYCATION END-PRODUCT; GLUCOSE-METABOLISM; STRESS MARKERS; IMPACT;
D O I
10.1016/j.clgc.2019.09.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article focuses on prostate cancer (PCa) progression. The study population consisted of patients recruited from urologic clinics at the University of Cincinnati Medical Center. Our study suggests that lipid oxidation is an important mechanism for PCa progression and may serve as a biological predictor of PCa progression. Introduction: Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and glycation, are associated with PCa progression. Patients and Methods: We recruited 3 groups of patients from a urologic clinic at the University of Cincinnati Medical Center: men with PCa who had undergone prostatectomy, men with PCa under watchful waiting, and men with benign prostatic hyperplasia (BPH). We used the most commonly used lipid oxidation marker, F2-isoprostanes; global oxidation markers, fluorescent oxidation products (FIOPs); and the commonly used marker for advanced glycation end products, carboxymethyllysine. These biomarkers were measured in plasma samples at baseline entry. Plasma prostate-specific antigen (PSA) was measured at enrollment and follow-up visits. Results: Compared with men with BPH, men with PCa who had undergone prostatectomy had 26% (P = .01) higher levels of F2-isoprostanes and 20% (P = .08) higher levels of carboxymethyllysine. All the oxidation markers were similar when comparing men under watchful waiting with men with BPH. When examining the associations between baseline oxidation markers and follow-up PSAs, we found that different oxidation markers had differential patterns associated with PSA elevation. F2-isoprostanes were positively associated with PSA elevation among men with PCa; FIOP_320 was positively associated with PSA elevation among both men with PCa and men with BPH, whereas among men with PCa under watchful waiting, FIOP_360 and FIOP_400 had opposite trends of associations with PSA elevation. Conclusions: Our study suggested that high levels of lipid oxidation were associated with PCa progression, whereas different global oxidation markers had different patterns associated with PCa progression. Large-scale clinical studies are needed to confirm our associations. Our study provides a comprehensive view of the relationship between biomarkers and PCa progression. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:E174 / E179
页数:6
相关论文
共 50 条
  • [1] Biomarkers and Prostate Cancer Progression
    Fillon, Mike
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (21) : 1570 - 1571
  • [2] EMT biomarkers in prostate cancer progression
    Whiteland, H.
    Spencer-Harty, S.
    Thomas, H.
    Davies, C.
    Bose, P.
    Fenn, N.
    Morgan, C.
    Doak, S.
    Kynaston, H.
    Jenkins, S.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 : 56 - 56
  • [3] Identification of novel biomarkers correlated with prostate cancer progression by an integrated bioinformatic analysis
    Ma, Zhifang
    Wang, Jianming
    Ding, Lingyan
    Chen, Yujun
    [J]. MEDICINE, 2020, 99 (28) : E21158
  • [4] Proteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer progression
    Shin, Kyeong Jin
    Seo, Young-kyo
    Yoo, Youngbum
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [5] BIOMARKERS ASSOCIATED WITH PROSTATE-CANCER PROGRESSION
    ZHAU, HE
    PISTERS, LL
    HALL, MC
    ZHAO, LS
    TRONCOSO, P
    POLLACK, A
    CHUNG, LWK
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 208 - 216
  • [6] Prostate Cancer: MicroRNA Biomarkers for Tumor Progression
    Kuner, R.
    Brase, J. C.
    Johannes, M.
    Faelth, M.
    Kuehlwein, T.
    Gade, S.
    Beissbarth, T.
    Haese, A.
    Schlomm, T.
    Sueltmann, H.
    [J]. ONKOLOGIE, 2010, 33 : 13 - 14
  • [7] PATTERNS OF PROGRESSION IN PROSTATE-CANCER
    MCNEAL, JE
    KINDRACHUK, RA
    FREIHA, FS
    BOSTWICK, DG
    REDWINE, EA
    STAMEY, TA
    [J]. LANCET, 1986, 1 (8472): : 60 - 63
  • [8] IDENTIFICATION OF NEW PROSTATE-CANCER PROGRESSION MARKERS BY DIFFERENTIAL HYBRIDIZATION ANALYSIS
    SCHALKEN, JA
    DEBRUYNE, FMJ
    [J]. EUROPEAN UROLOGY, 1992, 21 : 60 - 65
  • [9] Patterns of Differential Gene Expression May Provide Potential Biomarkers for Anal Cancer Progression
    Hendrick, Leah E.
    Ajidahun, Abidemi
    Wong, Denise
    Elahi, Abul
    Siegel, Erin
    Berglund, Anders
    Getun, Irina
    Kansal, Rita
    Glazer, Evan
    Shibata, David
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 343 - 343
  • [10] iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer
    Rehman, Ishtiaq
    Evans, Caroline A.
    Glen, Adam
    Cross, Simon S.
    Eaton, Colby L.
    Down, Jenny
    Pesce, Giancarlo
    Phillips, Joshua T.
    Yen, Ow Saw
    Thalmann, George N.
    Wright, Phillip C.
    Hamdy, Freddie C.
    [J]. PLOS ONE, 2012, 7 (02):